Table 1 Risk of adverse clinical events and relationship with ABC pathway in clinically complex, frail, multimorbid and polypharmacy patients (n=6091)

 ABC adherent, vs. non-adherent

0.72 [0.58–0.91]

0.63 [0.38–1.04]

0.71 [0.57–0.89]

0.86 [0.66–1.11]

 1 ABC criteria, vs. 0

0.53 [0.35–0.78]

0.50 [0.32–0.79]

0.51 [0.34–0.76]

0.52 [0.29–0.95]

 2 ABC criteria, vs. 0

0.34 [0.23–0.50]

0.37 [0.23–0.58]

0.32 [0.21–0.47]

0.39 [0.22–0.69]

 3 ABC criteria, vs. 0

0.29 [0.19–0.44]

0.28 [0.15–0.53]

0.27 [0.18–0.42]

0.37 [0.20–0.68]

 For each criteria

0.69 [0.62–0.78]

0.67 [0.56–0.80]

0.68 [0.60–0.76]

0.80 [0.68–0.93]

 2–3 ABC criteria, vs. 0–1

0.56 [0.47–0.68]

0.61 [0.46–0.81]

0.55 [0.45–0.66]

0.68 [0.53–0.88]

 ABC adherent, vs. non-adherent

0.68 [0.52–0.87]

0.88 [0.54–1.42]

0.69 [0.53–0.88]

0.80 [0.60–1.06]

 1 ABC criteria, vs. 0

0.69 [0.42–1.12]

0.57 [0.33–0.98]

0.64 [0.39–1.06]

0.63 [0.29–1.33]

 2 ABC criteria, vs. 0

0.45 [0.28–0.74]

0.41 [0.23–0.71]

0.44 [0.27–0.71]

0.58 [0.28–1.20]

 3 ABC criteria, vs. 0

0.36 [0.21–0.60]

0.44 [0.22–0.85]

0.35 [0.21–0.58]

0.48 [0.23–1.02]

 For each criteria

0.71 [0.62–0.81]

0.75 [0.61–0.92]

0.71 [0.63–0.82]

0.85 [0.72–1.00]

 2–3 ABC criteria, vs. 0–1

0.59 [0.47–0.73]

0.66 [0.48–0.91]

0.60 [0.48–0.75]

0.83 [0.61–1.12]

 ABC adherent, vs. non-adherent

0.70 [0.58–0.85]

0.75 [0.50–1.12]

0.70 [0.58–0.85]

0.82 [0.66–1.03]

 1 ABC criteria, vs. 0

0.65 [0.45–0.95]

0.62 [0.40–0.95]

0.61 [0.42–0.90]

0.58 [0.33–1.00]

 2 ABC criteria, vs. 0

0.43 [0.30–0.63]

0.46 [0.30–0.70]

0.41 [0.28–0.59]

0.46 [0.27–0.78]

 3 ABC criteria, vs. 0

0.35 [0.24–0.52]

0.41 [0.24–0.71]

0.33 [0.22–0.49]

0.41 [0.23–0.71]

 For each criteria

0.72 [0.65–0.79]

0.74 [0.63–0.87]

0.71 [0.64–0.79]

0.81 [0.71–0.92]

 2–3 ABC criteria, vs. 0–1

0.59 [0.50–0.70]

0.66 [0.52–0.85]

0.59 [0.50–0.70]

0.72 [0.57–0.90]